4D Molecular Therapeutics, Inc. (FDMT)
Automate Your Wheel Strategy on FDMT
With Tiblio's Option Bot, you can configure your own wheel strategy including FDMT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FDMT
- Rev/Share 0.0002
- Book/Share 8.4264
- PB 0.445
- Debt/Equity 0.0508
- CurrentRatio 12.3635
- ROIC -0.4112
- MktCap 173717250.0
- FreeCF/Share -2.7535
- PFCF -1.1318
- PE -1.1848
- Debt/Assets 0.0463
- DivYield 0
- ROE -0.3327
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Downgrade | FDMT | BMO Capital Markets | Outperform | Market Perform | $40 | $15 | Jan. 13, 2025 |
Downgrade | FDMT | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 23, 2024 |
News
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME).
Read More
4DMT to Participate in Upcoming Investor Conferences
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings.
Read More
4DMT to Participate in Upcoming Investor Conferences
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.
Read More
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About 4D Molecular Therapeutics, Inc. (FDMT)
- IPO Date 2020-12-11
- Website https://www.4dmoleculartherapeutics.com
- Industry Biotechnology
- CEO Dr. David H. Kirn M.D.
- Employees 227